Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, a, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R4, and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Abstract: Nuclear receptor LXR is an important member of 49 nuclear receptors in human bodies and has irreplaceable regulatory effects on cholesterol and fat metabolisms. The regulation of the biological activity of LXR may have therapeutic effects to the conditions such as cardiovascular and cerebrovascular obstructions, non-insulin dependent hyperglycemia, immune function disorders, and central nerve functional degeneration. We have developed a group of novel Chinese materia medica preparations targeting nuclear receptor LXR by using a computer-simulated docking technology and a process for determining biological activities of human cells cultured ex vivo. The group of preparations are featured by simple ingredients, low costs, easy to prepare, etc. No significant adverse effects were found in initial acute toxicology analysis which was carried out using mice.

Abstract: Disclosed is an extract obtained by a commercially viable process for the extraction of furostanolic saponins from fenugreek seeds, in which one of the compounds in the extract is protodioscin. The process includes providing plurality of fenugreek seeds and crushing the same by milling and grinding; performing a primary extraction on the prepared fenugreek seeds using a first hydrophilic polar solvent which is a lower primary aliphatic alcohol followed by ion-exchange chromatography; performing a secondary extraction after ion-exchange chromatography using a composite solvent; and decolorizing the final extract by use of activated charcoal concentration of the extract by heating and vacuum drying sieving the final powdered product.

Abstract: The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.

Abstract: The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating inflammation and cutaneous photodamage, which contains a water-soluble extract from a plant of Solanum genus. The composition also has a photoprotective effect, and can be used as a cosmetic composition.

Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.

Abstract: The present disclosure relates to a composition comprising Trigoneoside Ib and Vicenin-1 for treatment and management of Goodpasture's disease, Glomerulonephritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Idiopathic Thrombocytopenia Purpura. The present disclosure also relates to a method of obtaining the said composition from Trigonella foenum-graecum.

Abstract: Disclosed herein is an anti-wart pharmaceutical composition including a water-soluble extract from a plant of Solanum genus, the water-soluble extract comprising solamargine and solasonine. Also disclosed is a method for treating wart including applying to a subject in need of such treatment the water-soluble extract.

Abstract: A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination, and compositions of a synergistic combination of a cardiac glycoside and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be a taxane are also provided. The compositions may also be used in a method for modulating Na+K+ATPase activity. In addition, a method for inhibiting the progression or development of breast cancer in vivo by administering either actein or an extract of black cohosh comprising triterpene glycosides and optionally at least one other chemoprotective agent is provided.

Abstract: The present invention relates to a novel antiviral product, its use in the treatment of hepatitis C, and its process of manufacture. More particularly it relates to a characterised product exhibiting antiviral activity against Hepatitis C virus (HCV). In one embodiment there is provided a single herb Astragalus extract, or an active fraction thereof, for use as an antiviral in the treatment of hepatitis C.

Abstract: A method of inhibiting growth of cancer cells comprising contacting cancer cells with a 6-substituted estradiol derivative in an amount at least partially sufficient to inhibit said growth is disclosed. The compounds have the general formula depicted below, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein.

Abstract: The present invention provides methods of diagnosing migraine attacks and determining predisposition of an individual to the development of migraine based on sodium level in the cerebrospinal fluid (CSF) and/or brain extracellular fluid. The invention also provides methods of treating migraine, wherein the individual is selected for treatment based in the individual's sodium level in the CSF and/or brain extracellular fluid. The CSF sodium level may be based on the sodium concentration in the saliva.

Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Abstract: A composition for the alleviation or treatment of one or more symptoms caused by one or more conditions or diseases selected from the group consisting of dilated cardiomyopathy, acquired or naturally occurring valvular disease, hypertrophic cardiomyopathy, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy and unclassified cardiomyopathy and combinations thereof. Also disclosed is a kit and a method for alleviating or treating the symptoms.

Abstract: A series cardenolide derivatives including structure of formula I from the root of Reevesia formosana have provided. In formula (1) and (2), where R3, R5, R10 and R16 are as defined in the specification. The derivatives compounds showed potent cytotoxicity against MCF-7, NCI-H460, and HepG2 cancer cell lines.

Abstract: The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.

Abstract: As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.

Abstract: A supercritical fluid (SCF) extract of a cardiac glycoside-containing plant mass is provided. The extract can be included in a pharmaceutical composition containing an extract-solubilizing amount of solubilizer. Oleandrin is included within the extract when a cardiac glycoside-containing plant, such as Nerium oleander, is extracted by SCF extraction. The extract can also contain one or more other SCF extractable pharmacologically active agents. The composition can be used to treat a wide range of disorders that are therapeutically responsive to a cardiac glycoside.

Abstract: A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination, and compositions of a synergistic combination of a cardiac glycoside and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be a taxane are also provided. The compositions may also be used in a method for modulating Na+K+ATPase activity. In addition, a method for inhibiting the progression or development of breast cancer in vivo by administering either actein or an extract of black cohosh comprising triterpene glycosides and optionally at least one other chemoprotective agent is provided.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract: A method is provided for treating, preventing or ameliorating neoplasia in a subject. This method includes administering to the subject an amount of actein or an amount of an extract of black cohosh that contains a triterpene glycoside, which amount of the actein or black cohosh is effective to treat, prevent or ameliorate the neoplasia, in combination with an amount of a statin which is effective to treat, prevent, or ameliorate the neoplasia. Related methods for treating, preventing or ameliorating breast cancer, or liver cell neoplasia are also provided. In addition, methods for modulating a cholesterol biosynthesis pathway and a stress response pathway in a subject are provided. These methods include administering to a subject a composition comprising an anti-neoplastic synergistic amount of a statin and actein. Compositions for carrying out such methods are also provided.

Abstract: The present invention related to an antihypertensive composition containing a fraction enriched with ginsenosides of ginseng. The composition according to the present invention increases the production of nitric oxide through the activation of nitric oxide synthase, and thus exhibits superior antihypertensive effects through the vasodilatory activity. Consequently, the composition of the present invention can be used as a composition for preparing functional health foods for preventing and treating hypertension and various cardiovascular diseases caused by complications of hypertension.

Abstract: Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc-T are provided using compounds of the formula I wherein R1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1; R2 is H, —OH, C1-6 alkoxy or Sac 2; R3 is H, —OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof

Abstract: To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance, or improve the pathosis, the present invention provides an agent or a food or drink which contains 3-O-?-D-glucopyranosyl-4-methylergost-7-en-3-ol, or an organic solvent extract, a hot water extract or a squeezed liquid of a plant of the family Liliaceae or a fraction thereof which contains the compound as an active ingredient.

Abstract: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.

Abstract: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.

Abstract: The present invention features novel withanolides, as well as analogs and salts thereof, for use in the treatment of proliferative disease, cardiovascular disease, neurodegenerative disease and inflammatory disease.

Abstract: A saponin or a sapogenin, or a saponin or sapogenin derivative, from a plant of the capsicum genus for use in the treatment of a disease other than eczema and dermatitis. A process for preparing a plant of the capsicum genus, extracts, or seeds thereof for use as a medicament suitable for the treatment of diseases other than skin conditions which process comprises storing the plant, extracts or seeds thereof at a temperature of 20° C. or below.

Abstract: The present invention provides regio- and stereoselective oxidation of unactivated C—H bonds using an engineered mutant cytochrome P450 monooxygenase and an engineered substrate.

Abstract: Formulations and methods for increasing efficacies and flavors of jiaogulan (Gynostemma pentaphyllum and related species) by combining materials derived from whole plant with other herbal and nutritional materials for the purpose of improving general well-being in mammals by increasing metabolic rate through fatigue-reducing, tonic, antioxidant and adaptogenic effects of the invention.

Abstract: A method of improving the appearance of facial texture may comprise the step of applying a composition comprising an effective amount of a material that regulates hyaluronic acid synthesis to an area of textured facial skin, wherein the composition is applied for a period of time sufficient for the material to improve the appearance of the facial texture. In some embodiments, the material that regulates hyaluronic acid synthesis is hexyldecanol. The method may also include the step of identifying facial texture on a facial skin surface. In particular embodiments, the facial skin texture is selected from the group consisting of macro-texture, micro-texture, and combinations thereof.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract: A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5˜10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1˜30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40˜100° C., the ratio of these two is 1:1˜300, add water after the solvent is recycled under reduced pressure; another kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution contains 0.1˜2 mg/ml of 20 (R) of the ginsenoside Rg3, the preparation: add 0.1˜5% of ginsenoside solution to 20˜65% of adjuvant B{circle around (3)}{circle around (4)} at the temperature of 60˜100° C., main material to adjuvant B=1:100˜400, add water after the solvent is recycled under reduced pressure.

Abstract: A process for producing micronized dispersed micro-particles and to micro-particles produced by this process.

Abstract: A method of improving the appearance of facial pores is provided. The method includes the step of applying a composition having an effective amount of a material that regulates IL-1 and/or hyaluronic acid synthesis to an area of facial pores, wherein the composition is applied for a period of time sufficient for the material to improve the appearance of the facial pores. In some embodiments, the material that regulates IL-1 and/or hyaluronic acid synthesis is hexyldecanol. The method may also include the step of identifying facial pores on a facial skin surface.

Abstract: A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of formula I to a patient in need thereof wherein: R1 is H, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 alkoxy or C1-6-alkoxy-C1-6-alkyl; R2 is H, —OH or C1-6 alkoxy; S1 and S2 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester thereof.

Abstract: A method of treating neurological condition in a subject by administration of an extract, or fraction or sub-fraction thereof, of Nerium species or Thevetia species is provided, wherein the extract, or fraction or sub-fraction thereof, excludes oleandrin and neriifolin. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of the extract, or a fraction or sub-fraction thereof, to a subject. The extract can be present in a pharmaceutical composition.

Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Abstract: A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin.

Abstract: There are provided a promoter containing ginsenoside compound K for the production of hyaluronic acid, and more particularly, a new efficacy of 20-O-?-D-glucopyranosyl-20(S)-protopanaxadiol (compound K), a chief metabolite of ginseng saponin, to increase the expression of hyaluronic acid synthase gene in human cell and thereby to promote the production of hyaluronic acid, and an anti-aging agent containing the promoter for the production of hyaluronic acid as an effective ingredient.

Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.

Abstract: A method of treating a disease associated with cartilage defect in a subject in need thereof by administering to the subject an effectively amount of a cycloartane compound of Formula (I).

Abstract: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3?-yl)-?-D-glucopyranosiduronate, 16?,3?-dihydroxy-5?-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

Abstract: The invention concerns an extract of Centella asiatica comprising more than 75 wt. % of a mixture of madecassoside, terminoloside and asiaticoside, relative to the extract total weight, an extract of Centella asiatica comprising more than 95 wt. % of a mixture of madecassoside and terminoloside relative to the extract total weight and their use for regulating inflammatory mechanisms.

Abstract: For the prevention and/or treatment of chymase-mediated diseases such as skin diseases, circulatory diseases, digestive system diseases, respiratory diseases, liver diseases, ocular diseases or the like, a drug is provided having as an active ingredient a compound having extremely strong chymase inhibitory activity, high safety, and high metabolic stability. The compound represented by the formula (I): wherein all symbols have the same meanings as in the description, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a pharmaceutical ingredient having chymase inhibitory activity for preventing and/or treating of chymase-mediated disease, such as skin diseases, circulatory diseases, digestive system diseases, respiratory diseases, liver diseases, ocular diseases or the like.

Abstract: The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitosterol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside).